Universidad Veracruzana/Centro de Investigaciones Cerebrales, Xalapa, Veracruz, Mexico.
Centro Médico Cordobés, Córdoba, Veracruz, México.
Pharmacol Rep. 2020 Dec;72(6):1538-1541. doi: 10.1007/s43440-020-00168-1. Epub 2020 Oct 10.
We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine.
In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days.
This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2.
Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.
我们对来自墨西哥东南部地区的 15 名有 SARS-CoV-2 症状的患者进行了一项观察性研究，这些患者使用抗病毒药物金刚烷胺进行治疗。
在这项研究中，我们从 15 名有 COVID-19 感染临床症状的个体中收集数据，这些患者采用金刚烷胺 100mg 进行为期 14 天的门诊治疗。
该药物显示出其有效性，因为所有患者均成功康复，无需住院使用机械通气。所有患者均产生了针对 SARS-CoV-2 的 IgG 抗体。
在没有疫苗的情况下，金刚烷胺可作为一种可行且具有成本效益的替代药物，用于对严重急性呼吸综合征（SARS-CoV-2）患者进行门诊治疗。
